コメント 0

2012年 英文

原著

1)     Hatta M, Endo S, Tokuda K, Kunishima H, Arai K, Yano H, Ishibashi N, Aoyagi T, Yamada M, Inomata S, Kanamori H, Gu Y, Kitagawa M, Hirakata Y, and Kaku M: Post-Tsunami Outbreaks of Influenza in Evacuation Centers in Miyagi Prefecture, Japan. Clin Infect Dis. 2012;54(1):e5-7

2)     Kobayashi T, Saji T, Otani T, Takeuchi K, Nakamura T, Arakawa H, Kato T, Hara T, Hamaoka K, Ogawa S, Miura M, Nomura Y, Fuse I, Ichida F, Seki M, Ryuji Fukazawa, Chitose Ogawa, Kenji Furuno, Hirohide Tokunaga, Shinichi Takatsuki, Shinya Hara, Akihiro Morikawa. Efficacyof immunoglobulin plus prednisolone for prevention of coronary artery abnormalitiesin severe Kawasaki disease: a prospective, randomised, open, blinded-endpoint trial. Lancet 2012;379:1613-1620,

3)     Kodama Y, Okamoto Y, Hashiguchi T, Shinkoda Y, Nishikawa T, Tanabe T, Kawano Y. Vascular endothelial growth factor corrected by the platelet count and hematocrit is associated with the clinical course of aplastic anemia in children. Int J Hematol 95:494-499, 2012

4)     Nishikawa T, Miyahara E, Horiuchi M, Izumo K, Okamoto Y, Kawai Y, Kawano Y, Takeuchi T.Benzene Metabolite 1,2,4-Benzenetriol Induces Halogenated DNA and Tyrosines Representing Halogenative Stress in the HL-60 Human Myeloid Cell Line. Environ Health Perspect. 120:62-67, 2012

5)     Nomura Y, Arata M, Masuda K, Koriyama C, Suruki N, Ueno K, Yoshikawa H, Eguchi T, Kawano Y. Kawasaki disease patients with six principal symptoms have a high risk of being a nonresponder. Pedistr Int 54:14-18, 2012

6)     Onouchi Y, Ozaki K, Burns JC, Shimizu C, Terai M, Hamada H, Honda T, Suzuki H, Suenaga T, Takeuchi T, Yoshikawa N, Suzuki Y, Yasukawa K, Ebata R, Higashi K, Saji T, Kemmotsu Y, Takatsuki S, Ouchi K, Kishi F, Yoshikawa T, Nagai T, Hamamoto K, Sato Y, Honda A, Kobayashi H, Sato J, Shibuta S, Miyawaki M, Oishi K, Yamaga H, Aoyagi N, Iwahashi S, Miyashita R, Murata Y, Sasago K, Takahashi A, Kamatani N, Kubo M, Tsunoda T, Hata A, Nakamura Y, Tanaka T, Japan Kawasaki Disease Genome Consortium, Abe J, Kobayashi T, Arakawa H, Ichida F, Nomura Y, Miura M, Ikeda K, Hara T, Fukazawa R, Ogawa S, Hamaoka K; US Kawasaki Disease Genetics Consortium, Newburger JW, Baker AL, Rowley AH, Shulman ST, Melish ME, Mason WH, Takahashi M, Tremoulet AH. A genome-wide association study identifies three new risk loci for Kawasaki disease. Nat Genet 44:517-521, 2012

7)     Ueno K, Nomura Y, Masamoto I, Masuda K, Morita Y, Eguchi T, Okamoto Y, Kawano Y. Potential role of autoantibody in severe neutropenia of a patient with kawasaki syndrome. Scand J Immunol. 2012;75:120-126.

8)     Yoshikawa H, Nomura Y, Masuda K, Koriyama C, Arata M, Hazeki D, Yanagimoto K, Ueno K, Eguchi T, Kawano Y. Serum procalcitonin value is useful for predicting severity of Kawasaki disease. Pedatr Infect Dis J 31: 523-525, 2012

9)     Nishikawa T, Nakashima K, Fukano R, Okamura J, Inagaki J. Successful treatment with plasma exchange for disseminated cidofovir-resistant adenovirus disease in a pediatric SCT recipient. Bone Marrow Transplant.2012;47(8):1138-9

10)   Maruyama S, Saito Y, Nakagawa E, Saito T, Komaki H, Sugai K, Sasaki M, Kumada S, Saito Y, Tanaka H, Minami N, Goto Y. Importance of CAG repeat length in childhood-onset dentatorubral-pallidoluysian atrophy. J Neurol. 2012;259(11):2329-34

11)   Nishikawa T, Inagaki J, Nagatoshi Y, Fukano R, Nakashima K, Ito N, Sawa D, Kawano Y, Okamura J. The second therapeutic trial for children with hematological malignancies who relapsed after their first allogeneic SCT: Long-term outcomes. Pediatr Transplant. 2012;16(7):722-8

12)     Ayako A, Shintani M, Yagi H, Fujiwara M, Kojima Y, Sato H, Imamura S, Yokozawa M, Onodera N, Horigome H, Kobayashi T, Hatai Y, Nakayama T, Fukushima H, Nishiyama M, Doi S, Ono Y,  Yasukouchi S, Ichida F, Fujimoto K, Ohtsuki S, Teshima H, Kawano T, Nomura Y, Gu H, Ishiwata T, Furutani Y, Inai K, Saji T, Matsuoka R, Nonoyama S, Nakanishi T. Outcomes of Childhood Pulmonary Arterial Hypertension in BMPR2 and ALK1 Mutation Carriers. Am J Cardiol. 2012;110(4):586-593.

13)   Koike T, Harigai M,  Ishiguro N,  Inokuma S, Takei S, Tsutomu Takeuchi T, Yamanaka H, Tanaka Y. Safety and effectiveness of adalimumab in Japanese patients with rheumatoid arthritis: a report of the first 3,000 patients treated during postmarketing surveillance. Mod Rheumatol 2012,22:498-508.

14)   Yokota S, Imagawa T, Murata T, Tomiita M, Itoh Y, Fujikawa S, Takei S, Mori M. Guidance on the use of adalimumab for juvenile idiopathic arthritis in Japan. Mod Rheumatol 2012,22:491-497

15)   Imagawa T, Takei S, Umebayashi H, Yamaguchi K, Itoh Y, Kawai T, Iwata N, Murata T, Okafuji I, Miyoshi M, Onoe Y, Kawano Y, Kinjo N, Mori M, Mozaffarian N, Kupper H, Santra S, Patel G, Kawai S, Yokota S. Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan. Clin Rheumatol. 2012 Dec,31(12):1713-21.

16)   Suematsu R, Ohta A, Matsuura E, Takahashi H, Fujii T, Horiuchi T, Minota S, Ishigatsubo Y, Ota T, Takei S, Soejima S, Inoue H, Koarada S, Tada Y, Nagasawa K. Therapeutic response of patients with adult Still’s disease to biologic agents: multicenter results in Japan. Mod Rheumatol 2012,22:712-719.

17)   Mori M, Takei S, Imagawa T, Imanaka H, Nerome Y, Higuchi R, Kawano Y, Yokota S, Sugiyama N, Yuasa H, Eletcher T, Wajdule JS. Safety and efficacy of long-term eatanercept in the treatment of methotrexate-reflactory polyarticular-course juvenile idiopathic arthritis in Japan. Mod Rheumatol 2012,22:720-726.

18)   Yonee C, Toyoshima M, Young SP, Maruyama S, Higuchi I, Narita A, Maegaki Y, Nanba E, Ohno K, Kawano Y. Quantitative computed tomography for enzyme replacement therapy in Pompe disease. Brain Dev 2012 Nov,34(10):834-9.

19)   Fukao T, Maruyama S, Ohura T, Hasegawa Y, Toyoshima M, Haapalainen AM, Kuwada N, Imamura M, Yuasa I, Wierenga RK, Yamaguchi S, Kondo N. Three Japanese Patients with Beta-Ketothiolase Deficiency Who Share a Mutation, c.431A>C (H144P) in ACAT1 : Subtle Abnormality in Urinary Organic Acid Analysis and Blood Acylcarnitine Analysis Using Tandem Mass Spectrometry. JIMD Rep. 2012;3:107-15.

著書

1)     Juvenile Idiopathic Arthritis (JIA): Theory and practicality of tocilizumab treatment. Ed., Takei S, Yokota S, Springer, London, 2012.

コメントを残す

以下に詳細を記入するか、アイコンをクリックしてログインしてください。

WordPress.com ロゴ

WordPress.com アカウントを使ってコメントしています。 ログアウト /  変更 )

Google フォト

Google アカウントを使ってコメントしています。 ログアウト /  変更 )

Twitter 画像

Twitter アカウントを使ってコメントしています。 ログアウト /  変更 )

Facebook の写真

Facebook アカウントを使ってコメントしています。 ログアウト /  変更 )

%s と連携中